Stoke Therapeutics, Inc. - Common Stock, par value $0.0001 per share (STOK)

Historical Holders from Q2 2019 to Q1 2025

Symbol
STOK on Nasdaq
CUSIP
86150R107
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
53.2M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
58.1M
Holdings value
$640M
% of all portfolios
0.014%
Grand Portfolio weight change
0%
Number of holders
128
Number of buys
61
Number of sells
-55
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Stoke Therapeutics, Inc. - Common Stock, par value $0.0001 per share (STOK)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Skorpios Trust 13% $45.9M 6.91M Skorpios Trust Dec 23, 2024
RTW INVESTMENTS, LP 9.99% $35.3M 5.31M RTW Investments, LP Dec 31, 2024
MORGAN STANLEY 6.5% $22.8M 3.43M Morgan Stanley Dec 31, 2024
BlackRock, Inc. 5.8% $20.7M 3.12M BlackRock, Inc. Mar 31, 2025
BlackRock Portfolio Management LLC 5.1% $18.2M 2.74M BlackRock Portfolio Management LLC Mar 31, 2025

Institutional Holders of Stoke Therapeutics, Inc. - Common Stock, par value $0.0001 per share (STOK)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 1.03M $6.86M -$2.58M $6.65 8
2024 Q4 58.1M $640M -$5.65M $11.03 128
2024 Q3 58.2M $715M -$45.8M $12.29 117
2024 Q2 61.3M $828M +$97.1M $13.51 115
2024 Q1 54.1M $730M +$114M $13.50 103
2023 Q4 45M $237M +$4.38M $5.26 81
2023 Q3 43.9M $173M -$18.2M $3.94 96
2023 Q2 46.5M $494M +$20.7M $10.63 96
2023 Q1 44.6M $372M +$14.2M $8.33 96
2022 Q4 40.3M $372M -$19.2M $9.23 105
2022 Q3 38.9M $499M +$1.44M $12.84 95
2022 Q2 40.4M $535M +$3.68M $13.21 84
2022 Q1 38.8M $817M +$73M $21.05 95
2021 Q4 35.4M $848M +$26.4M $23.99 90
2021 Q3 19.3M $492M -$27.8M $25.44 88
2021 Q2 20.2M $680M -$703M $33.66 96
2021 Q1 38.4M $1.49B -$15.7M $38.84 104
2020 Q4 38.4M $2.38B +$253M $61.93 90
2020 Q3 34.6M $1.16B +$2.94M $33.49 89
2020 Q2 34.9M $825M +$9.8M $23.83 69
2020 Q1 34.6M $791M +$23.3M $22.90 65
2019 Q4 33.5M $948M +$22.4M $28.32 63
2019 Q3 15.9M $339M +$30.1M $21.49 52
2019 Q2 14.2M $408M +$408M $29.17 46